These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus. Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A Molecules; 2020 May; 25(11):. PubMed ID: 32485894 [TBL] [Abstract][Full Text] [Related]
3. Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease. Akaji K; Konno H Molecules; 2020 Aug; 25(17):. PubMed ID: 32867349 [TBL] [Abstract][Full Text] [Related]
4. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy. Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346 [TBL] [Abstract][Full Text] [Related]
5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing. Kumar Y; Singh H; Patel CN J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274 [TBL] [Abstract][Full Text] [Related]
6. Biochemical and Computational Approach of Selected Phytocompounds from Rakib A; Paul A; Chy MNU; Sami SA; Baral SK; Majumder M; Tareq AM; Amin MN; Shahriar A; Uddin MZ; Dutta M; Tallei TE; Emran TB; Simal-Gandara J Molecules; 2020 Aug; 25(17):. PubMed ID: 32872217 [TBL] [Abstract][Full Text] [Related]
8. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses. Theerawatanasirikul S; Kuo CJ; Phecharat N; Chootip J; Lekcharoensuk C; Lekcharoensuk P Antiviral Res; 2020 Oct; 182():104927. PubMed ID: 32910955 [TBL] [Abstract][Full Text] [Related]
9. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306 [TBL] [Abstract][Full Text] [Related]
10. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2. Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265 [TBL] [Abstract][Full Text] [Related]
11. Reckoning a fungal metabolite, Pyranonigrin A as a potential Main protease (M Rao P; Shukla A; Parmar P; Rawal RM; Patel B; Saraf M; Goswami D Biophys Chem; 2020 Sep; 264():106425. PubMed ID: 32663708 [TBL] [Abstract][Full Text] [Related]
12. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166 [TBL] [Abstract][Full Text] [Related]
13. Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M Abu-Melha S; Edrees MM; Riyadh SM; Abdelaziz MR; Elfiky AA; Gomha SM Molecules; 2020 Oct; 25(19):. PubMed ID: 33036293 [TBL] [Abstract][Full Text] [Related]
14. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors. Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388 [TBL] [Abstract][Full Text] [Related]
15. Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease. Kandeel M; Al-Nazawi M Life Sci; 2020 Jun; 251():117627. PubMed ID: 32251634 [TBL] [Abstract][Full Text] [Related]
16. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2. Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701 [TBL] [Abstract][Full Text] [Related]
17. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
18. Tannins inhibit SARS-CoV-2 through binding with catalytic dyad residues of 3CL Khalifa I; Zhu W; Mohammed HHH; Dutta K; Li C J Food Biochem; 2020 Oct; 44(10):e13432. PubMed ID: 32783247 [TBL] [Abstract][Full Text] [Related]
19. Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel Sencanski M; Perovic V; Pajovic SB; Adzic M; Paessler S; Glisic S Molecules; 2020 Aug; 25(17):. PubMed ID: 32842509 [TBL] [Abstract][Full Text] [Related]
20. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Abian O; Ortega-Alarcon D; Jimenez-Alesanco A; Ceballos-Laita L; Vega S; Reyburn HT; Rizzuti B; Velazquez-Campoy A Int J Biol Macromol; 2020 Dec; 164():1693-1703. PubMed ID: 32745548 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]